Companion Diagnostics And Deal-making On The Stage At PSA
This article was originally published in The Pink Sheet Daily
Executive Summary
Panelists at Elsevier’s Pharmaceutical Strategic Alliances conference say the need for companion diagnostics and biomarkers, particularly in oncology, are influencing deal-making negotiations and raising questions about how to define the value of a diagnostic test relative to the therapeutic.